Clinical Research Directory
Browse clinical research sites, groups, and studies.
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
Sponsor: Mirador Therapeutics, Inc.
Summary
First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-201 in Healthy Participants
Key Details
Gender
All
Age Range
19 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2025-10-08
Completion Date
2026-12-31
Last Updated
2025-11-04
Healthy Volunteers
Yes
Conditions
Interventions
MT-201
MT-201
Placebo
Placebo
Locations (1)
Mirador Clinical Department, San Diego, California 92121
San Diego, California, United States